MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
26.54
+0.54
+2.08%
After Hours: 26.54 0 0.00% 16:05 05/13 EDT
OPEN
26.00
PREV CLOSE
26.00
HIGH
26.54
LOW
25.75
VOLUME
24.91K
TURNOVER
--
52 WEEK HIGH
31.32
52 WEEK LOW
8.13
MARKET CAP
248.30M
P/E (TTM)
-0.5696
1D
5D
1M
3M
1Y
5Y
1D
TVARDI THERAPEUTICS INC - COMPLETES MERGER WITH CARA THERAPEUTICS
Reuters · 2h ago
Press Release: Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
Dow Jones · 3h ago
Weekly Report: what happened at TVRD last week (0505-0509)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Tourmaline Bio (TRML), Tvardi Therapeutics (TVRD)
TipRanks · 05/05 11:30
Weekly Report: what happened at TVRD last week (0428-0502)?
Weekly Report · 05/05 11:13
Cognex, Editas, Akebia, Tvardi, Chipotle: Trending by Analysts
TipRanks · 05/03 09:01
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/02 12:07
Tvardi Therapeutics initiated with a Buy at Lucid Capital
TipRanks · 04/30 11:35
More
About TVRD
More
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Recently
Symbol
Price
%Change

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.